Nazione: Canada
Lingua: inglese
Fonte: Health Canada
INDOMETHACIN
RHOXALPHARMA INC
C01EB03
INDOMETACIN
100MG
SUPPOSITORY
INDOMETHACIN 100MG
RECTAL
10/30
Prescription
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0101832003; AHFS:
APPROVED
2004-08-12
PRODUCT MONOGRAPH RHODACINE INDOMETHACIN SUPPOSITORIES USP 100 MG NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT RHOXALPHARMA INC. 4600 THIMENS BOULEVARD MONTREAL, QUEBEC H4R 2B2 CONTROL #: 093319 DATE OF PREPARATION : AUGUST 12, 2004 Page 2 PRODUCT MONOGRAPH RHODACINE INDOMETHACIN SUPPOSITORIES USP 100 MG NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT PHARMACEUTICAL / THERAPEUTIC CLASSIFICATION Nonsteroidal anti-inflammatory analgesic agent ACTION AND CLINICAL PHARMACOLOGY Indomethacin is a nonsteroidal anti-inflammatory drug with marked analgesic, and antipyretic properties. It has a unique chemical structure, which differentiates it from the salicylates, corticosteroids, phenylbutazone-like compounds and colchicine. Unlike corticosteroids, it has no effect on pituitary or adrenal function. Indomethacin is a potent inhibitor of prostaglandin synthesis _ in vitro_. Concentrations are reached during therapy which have been demonstrated to have an _in vivo_ effect as well. Although indomethacin does not alter the course of the underlying disease, it has been found effective to relieve pain, reduce fever, swelling and tenderness, and increase Page 3 mobility in patients with rheumatic diseases, including rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and gout. PHARMACOKINETICS: In man, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 _µ_g/mL at approximately 2 hours following single oral doses of 25 and 50 mg, respectively. Ninety percent of the orally administered indomethacin is absorbed within 4 hours. The suppository formulation is more rapidly and completely absorbed than the oral dose of indomethacin. Thus, C max after rectal administration is lower than after oral dosing. The mean half-life of indomethacin is estimated to be about 4.5 hours. With a typical therapeutic regimen of 25 or 50 mg t.i.d., the steady state plasma concentrations of indomethacin are on average 1.4 times those following the first dose. Indomethacin exists in the plasma as the parent Leggi il documento completo